Business Wire

EUNETWORKS

22.4.2024 09:01:28 CEST | Business Wire | Press release

Share
euNetworks Adds a New High-Density Fibre Network in Brussels

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the addition of a new duct and fibre-based network in Brussels to its Pan-European network footprint. This new addition takes the company’s owned and operated metropolitan network count to 18 in Europe. This is the latest of the company’s investments in digital infrastructure in the Benelux region, following the addition of a duct-based fibre network in Belgium through acquisition in April 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422857344/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

euNetworks' Metropolitan Network in Brussels, Belgium. (Graphic: Business Wire)

Last year, the 1,660 kilometres of fibre network acquired added unique routes in Brussels and long haul routes across Belgium, delivering a solid complement to euNetworks’ in-place network in the region. It also presented compelling additional investment opportunities for euNetworks in the long haul, in adjacent geographies and in building a new Brussels city network to give customers a truly end-to-end experience.

Since then, euNetworks has invested further in the Brussels metropolitan area, overbuilding acquired duct, purchasing additional cable and duct, and building additional high fibre count connectivity and diversity between key data centre sites, clusters and network aggregation points to deliver this new Brussels footprint.

Brussels Metro:

  • 41 kilometres of duct and high-fibre count network
  • Connects 5 data centres day 1, including LCL Brussels-North, Digital Realty BRU1, BRU3 & BRU4, AtlasEdge Brussels BRU001
  • With multiple, diverse entry points to these on-net data centres
  • Additional data centres are in the pipeline to be connected to support customer demand
  • Dark Fibre, Long Haul and Metro Wavelengths and Ethernet-based services are available across this footprint, with four diverse 100G Ethernet nodes to be installed, delivering resiliency and redundancy
  • Seamless connectivity between Brussels connected data centres and other regional data centre clusters and hubs in Ghent, Antwerp, Charleroi and Saint Ghislain
  • With multiple diverse long haul connectivity options from Brussels

“Belgium is a growing digital hub, with significant investment in the region to support emerging technology trends such as IoT and GenAI, which drive Cloud adoption and strategies,” said Paula Cogan, Chief Executive Officer of euNetworks. “Our Brussels and wider Belgium investments strengthen our leadership in European critical infrastructure as we focus on the ongoing densification of the high-bandwidth demand region of FLAP (Frankfurt, London, Amsterdam and Paris). We continue our approach to deliver a differentiated proposition to the market, offering unique and scalable network routes to our customers between key data centres. We also have a strong pipeline of ongoing investment to continue to support their growing bandwidth needs, further capitalising on the investment we made last year. I’m very proud of what the team have accomplished in a relatively short timeframe, delivering our eighteenth metro network to market. We’ve also expanded our local operations and sales presence, enabling strong support for our customers locally as they move forward with their infrastructure investments.”

euNetworks builds and invests in city and long haul fibre networks to connect key European data centres and data hubs. The company owns and operates deep fibre networks in 18 cities as well as a highly differentiated long haul network that spans 45,000 route kilometres across 17 countries. As a specialist in the sector, euNetworks continues to grow and invest in partnership with its customers, investing in new technologies and deepening its unique fibre network in Europe.

About euNetworks

euNetworks is a critical bandwidth infrastructure company, owning and operating 18 fibre-based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 536 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs.

The company delivers services with an active commitment to sustainability and is focused on its path to being carbon emissions net zero, environmentally responsible supply chain management and working as a community and industry to collaborate on the environmental challenges ahead. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422857344/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye